Company news

Neumora Therapeutics, Inc. news in 2025

Neumora Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Neumora Therapeutics to Participate in Upcoming Conferences in November

November 3, 2025

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

October 27, 2025

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

October 27, 2025

Neumora Therapeutics to Host Virtual R&D Day on October 27

October 1, 2025

Neumora Therapeutics to Participate in Upcoming Conferences in September

September 2, 2025

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 23, 2025

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

July 9, 2025

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

March 4, 2025

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 3, 2025

Neumora Therapeutics Announces Leadership Transition

February 12, 2025

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

January 1, 2025

Calls in 2025

Decks in 2025